Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | POLA1 | P09884 | 1/20 | 0.51 |
| ▸ | POLG | P54098 | 1/20 | 0.51 |
| ▸ | FAP | Q12884 | 1/20 | 0.51 |
| ▸ | NSD3 | Q9BZ95 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SERPINA3 | P01011 | 1/20 | 0.43 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19370539 | 0.94 | FGFR1 (0.53) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL12339258 | 0.94 | FGFR1 (0.53) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL21577310 | 0.94 | FGFR1 (0.53) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL14839881 | 0.89 | ADCY5 (0.49) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL24808635 | 0.87 | CYP3A4 (0.59) | FAPCYP3A4 | |
| SCHEMBL14417996 | 0.87 | CYP3A4 (0.59) | FAPCYP3A4 | |
| SCHEMBL21991323 | 0.82 | SERPINA3 (0.53) | FGFR1SLC22A6ABCB11POLA1POLG | |
| SCHEMBL28038355 | 0.82 | CYP3A4 (0.54) | FAPCYP3A4 | |
| SCHEMBL28038352 | 0.82 | CYP3A4 (0.54) | FAPCYP3A4 | |
| SCHEMBL20067756 | 0.82 | FAP (0.49) | FAPEGFRBTN3A1CYP3A4ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268802-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8088754-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088754-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553825-B2 | Anti-proliferative compounds, compositions, and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149400-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | FGFR1 1503/4885SLC22A6 3330/4885ABCB11 2452/4885 |
| US-20090291922-A1 | ANTI-PROLIFERATIVE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | CCNY, CCNO, CCNB3 | FGFR1 1503/4885SLC22A6 3330/4885ABCB11 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.